FDA Form 483

Key facts

Official title

Inspectional Observations

Issued by

FDA investigators to firm management at the close of an inspection

Legal status

Not a final FDA determination that a violation occurred

Response

Voluntary; FDA considers replies received within 15 business days

Inspection outcomes

Classified as NAI, VAI or OAI after FDA review

What is FDA Form 483?

At the end of an inspection of a drug, device, biologics, food or other regulated facility, the Food and Drug Administration (FDA) investigator meets with management. If the investigator observed objectionable conditions, those observations are written on a Form 483 and handed to the firm.

The form records what the inspection team observed. It is not a final agency decision. FDA later reviews the observations together with the Establishment Inspection Report, collected evidence and the response of the firm before deciding whether regulatory action is warranted.

Not every inspection produces a 483. When investigators observe no objectionable conditions, no form is issued.

How the Form 483 process works

After the form is issued, the process usually runs as follows:

• Observations: each item describes a condition, such as inadequate investigation of out-of-specification test results, and items are generally listed in order of significance.
• Response: the firm may reply in writing. Under FDA policy, a response received within 15 business days is considered before the agency decides on further action, such as a warning letter.
• Classification: FDA closes the inspection as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI).
• Follow-up: an OAI outcome can lead to a warning letter, import alert, withheld approvals or other enforcement.

Why Form 483s matter

Form 483s are one of the earliest public signals of manufacturing problems:

• Supplier qualification: drug and device companies review the 483 history of contract manufacturers and ingredient suppliers before signing or renewing contracts.
• Early warning: a 483 with repeat or data integrity observations often precedes a warning letter and possible supply disruption.
• Due diligence: investors and acquirers read 483s to judge remediation cost and approval risk at a plant.
• Benchmarking: citation data in the FDA Data Dashboard shows which regulations are cited most often in each product area.

Limitations of Form 483 data

FDA posts only some 483s in its FOIA Electronic Reading Room. Others must be requested under the Freedom of Information Act and arrive redacted, sometimes long after the inspection.

Because the form captures investigator observations before FDA review and before the firm responds, it can overstate or understate the final regulatory outcome.